Comparative Pharmacology
Head-to-head clinical analysis: ORTHO NOVUM 7 7 7 28 versus TRI LINYAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO NOVUM 7 7 7 28 versus TRI LINYAH.
ORTHO-NOVUM 7/7/7-28 vs TRI-LINYAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of estrogen (ethinyl estradiol) and progestin (norethindrone) inhibits gonadotropin secretion, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
Combination hormonal contraceptive: ethinyl estradiol and norgestimate. Suppresses gonadotropin release, inhibiting ovulation; also increases cervical mucus viscosity and alters endometrial morphology.
One tablet orally once daily for 28 consecutive days (21 active tablets followed by 7 placebo tablets). Each active tablet contains 0.035 mg ethinyl estradiol and varying progestin doses: 7 tablets of 0.5 mg norethindrone, 7 tablets of 0.75 mg norethindrone, and 7 tablets of 1 mg norethindrone.
One tablet orally once daily for 21 days, followed by 7 placebo tablets. Each tablet contains 0.035 mg ethinyl estradiol and 0.180/0.215/0.250 mg norgestimate.
None Documented
None Documented
EE: terminal half-life 13-27 hours (mean ~17 hours); NET: 7-13 hours (mean ~10 hours). Clinical context: steady state reached after 4-7 days; missed pills may reduce contraceptive efficacy.
Ethinyl estradiol: terminal half-life approximately 17 hours (range 13–27 hours), supporting once-daily dosing; norgestimate's active metabolite norelgestromin: terminal half-life approximately 28 hours.
Ethinyl estradiol (EE) is excreted in urine (40%) and feces (60%) as glucuronide and sulfate conjugates. Norethindrone (NET) is excreted primarily in urine (60-80%) as glucuronide conjugates, with 10% in feces. Biliary excretion contributes minimally.
Ethinyl estradiol is excreted in urine (40%) and feces (60%) as glucuronide and sulfate conjugates; norgestimate is primarily eliminated via renal excretion (46%) and fecal excretion (47%) as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive